BioSpace News Archive

DBV Technologies announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the Company’s VITESSE Phase 3 clinical trial that will evaluate the modified Viaskin™ Peanut 250 μg patch in peanut-allergic children ages 4 to 7 years.

Bavarian Nordic A/S announced a new agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, for the advanced development of MVA-BN® WEV, a prophylactic vaccine candidate against Western, Eastern and Venezuelan equine encephalitis virus, which can cause a rare, but potentially deadly mosquito-borne illness in humans.

BioNTech SE announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company’s BNT165 program, to develop a multi-antigen malaria vaccine candidate.

Nykode Therapeutics ASA announced that its Chief Executive Officer Michael Engsig will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT / 10:30 p.m. CET.

Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. for the exclusive rights to develop and commercialize Winlevi® cream 1% and all future product extension and/or improvement in the treatment of acne in 10 countries across Southeast Asia.

Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application.

LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform.

Welltower® Inc. (NYSE: WELL) – In conjunction with the initial closing of the Integra Health joint venture, previously announced on November 7th, Welltower has issued the following presentation.

Intercept Pharmaceuticals, Inc. today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for obeticholic acid (OCA) for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

CytoDyn Inc. will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.